Roche Holding AG (0QQ6.L) LSE
320.54
-5.16999(-1.59%)
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
Roche Holding AG
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
103249
First IPO Date
March 07, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Thomas Schinecker | Group Chief Executive Officer | 3.87M | 1975 |
| Maria Cristina A. Wilbur | Chief People Officer | 2.92M | 1967 |
| Alan Hippe | Chief Financial Officer | 4.11M | 1967 |
| Severin Schwan | Executive Chairman | 7.51M | 1967 |
| Bruno Eschli | Head of Investor Relations | 0 | N/A |
| Boris L. Zaitra | Head of Corporate Business Development | 0 | 1972 |
| Claudia Bockstiegel | General Counsel | 0 | 1964 |
| Nina Schwab-Hautzinger | Head of Group Communications | 0 | 1975 |
| Nicolas Dunant | Head of Group Media Relations | 0 | N/A |
| Pascale Schmidt | Chief Compliance Officer | 0 | 1973 |
| Wafaa Mamilli | Chief Digital & Technology Officer | 0 | 1967 |
Description
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.
